Mitochondrial‐Targeting Mesoporous Polydopamine Nanoparticles for Reducing Kidney Injury Caused by Depleted Uranium
Wenrun Li,Li Shen,Shiyan Fu,Yong Li,Feng Huang,Qi Li,Qinyang Lin,Hongjia Liu,Qiuchi Wang,Liyi Chen,Huanhuan Tan,Juan Li,Yazhen Zhao,Yonghong Ran,Yuhui Hao
DOI: https://doi.org/10.1002/adhm.202403015
IF: 10
2024-11-20
Advanced Healthcare Materials
Abstract:A new mitochondrial targeted dual‐function nanoparticle MPDA–PEG–TPP is proposed and confirm that it has high selectivity and adsorption to uranyl and can effectively remove excess reactive oxygen. At the same time, MPDA–PEG–TPP can target mitochondria, reducing oxidative stress, and mitochondrial dysfunction caused by depleted uranium to improve kidney injury. Depleted uranium (DU), when accidentally released from the nuclear industry, can enter the human body and cause kidney damage, as DU induces oxidative damage and apoptosis through mitochondrial pathways and inflammatory reactions. The existing nanoparticles used to treat DU injury have low bioavailability and poor targeting. In this study, mesoporous polydopamine (MPDA), poly‐(ethylene glycol) (PEG), and triphenylphosphonium (TPP) are combined to develop a novel mitochondrion‐targeting bifunctional nanoparticle, MPDA–PEG–TPP, and confirm that it can protect the kidneys from DU. This study demonstrates the high selectivity of MPDA–PEG–TPP for uranyl in uranyl chelate assays and its promising efficiency in uranyl sequestration from the kidneys, lungs, and femurs, following immediate or delayed administration of MPDA–PEG–TPP nanoparticles. In vitro assays confirm its efficiency in removing reactive oxygen species and targeting the mitochondria. In addition, in vitro and in vivo assays confirm that MPDA–PEG–TPP can reduce mitochondrial dysfunction and ameliorate kidney injury. These results suggest that MPDA–PEG–TPP is a valuable agent for ameliorating the DU‐induced kidney injury.
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials